Klonoff DC, et al. - In participants with type 1 diabetes (T1D), researchers tested the safety and effectiveness of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in insulin pump therapy (or continuous subcutaneous insulin infusion [CSII]). This study investigates faster aspart (n = 236) or IAsp (n = 236) CSII treatment. Investigators found that faster aspart in relation to baseline change in glycated haemoglobin was non-inferior to IAsp. Faster aspart was higher than IAsp in 1-hour postprandial glucose (PPG) increase after a meal test, with statistically significant reductions at 30 minutes and 2 hours as well. After all meals, the improvement in PPG was reflected in the 1-hour interstitial glucose increase from baseline. In the overall rate of severe or blood glucose-confirmed hypoglycaemia, there was no statistically significant difference. According to this double-blind, treat-to-target, randomized, 16-week trial, faster aspart offers an effective and safe T1D treatment option for CSII.